公開(公告)號
|
CN101010078A
|
公開(公告)日
|
2007.08.01
|
申請(專利)號
|
CN200580027253.7
|
申請日期
|
2005.08.09
|
專利名稱
|
作為藥物的雜環(huán)化合物
|
主分類號
|
A61K31/426(2006.01)I
|
分類號
|
A61K31/426(2006.01)I;C07D277/04(2006.01)I
|
分案原申請?zhí)? |
|
優(yōu)先權(quán)
|
2004.8.10 US 60/600,239
|
申請(專利權(quán))人
|
埃克塞里艾克西斯公司
|
發(fā)明(設(shè)計)人
|
R·馬丁;B·T·弗拉特;J·D·卡爾
|
地址
|
美國加利福尼亞州
|
頒證日
|
|
國際申請
|
2005-08-09 PCT/US2005/028357
|
進入國家日期
|
2007.02.12
|
專利代理機構(gòu)
|
中國專利代理(香港)有限公司
|
代理人
|
王穎煜;梁 謀
|
國省代碼
|
美國;US
|
主權(quán)項
|
具有式(I)的化合物: 或其藥學(xué)可接受的衍生物,其中: 鍵a是單鍵或雙鍵; X1是NR6,O或S(O)t; X2是S或O; R1是任選取代的烷基,任選取代的烯基或任選取代的炔基,當(dāng)取代時,其所有的都被一至五個取代基取代,每個取代基獨立地選自:氰基,硝基,鹵素,擬鹵素,-OR10,-SR16,-N(R11)(R12),-C(J)R13,-C(J)OR10,-C(J)N(R11)(R12),-C(J)N(R10)N(R11)(R12),-N(R10)C(J)R13,-N(R10)C(J)OR10,-N(R10)C(J)N(R11)(R12),-OC(J)R13,-OC(J)OR10,-OC(J)N(R11)(R12),-Si(R14)3,-N(R10)S(O)tR15和-R9-S(O)tR15; 或R1是任選取代的環(huán)烷基,任選取代的環(huán)烷基烷基,任選取代的雜環(huán)基,任選取代的雜環(huán)烷基,任選取代的芳基,任選取代的芳烷基,任選取代的雜芳基或任選取代的雜芳烷基,當(dāng)取代時,所有的都被一至五個取代基取代,每個取代基獨立地選自:烷基,鹵代烷基,環(huán)烷基,環(huán)烷基烷基,雜環(huán)基,雜環(huán)烷基,芳基,芳烷基,雜芳基,雜芳烷基,氰基,硝基,鹵素,擬鹵素,-R9-OR10,-R9-SR16,-R9-N(R11)(R12),-R9-C(J)R13,-R9-C(J)OR10,-R9-C(J)N(R11)(R12),-R9-C(J)N(R10)N(R11)(R12),-R9-N(R10)C(J)R13,-R9-N(R10)C(J)OR10,-R9-N(R10)C(J) N(R11)(R12),-R9-OC(J)R13,-R9-OC(J)OR10,-R9-OC(J)N(R11)(R12),-Si(R14)3,-N(R10)S(O)tR15和-R9-S(O)tR15; 或R1是-R9-N(R11)(R12),-R9-C(J)R13,-R9-C(J)OR10,-R9-C(J)N(R11)(R12),-R9-N(R10)C(J)R13,-R9-N(R10)C(J)OR10,-R9-S(O)tR15or-R9-N(R10)C(J)N(R11)(R12); R2是任選取代的烷基,任選取代的烯基,任選取代的炔基,當(dāng)取代時,其所有的都被一至五個取代基取代,每個取代基獨立地選自:氰基,硝基,鹵素,擬鹵素,-OR10,-SR16,-N(R11)(R12),-C(J)R13,-C(J)OR10,-C(J)N(R11)(R12),-C(J)N(R10)N(R11)(R12),-N(R10)C(J)R13,-N(R10)C(J)OR10,-N(R10)C(J)N(R11)(R12),-OC(J)R13,-OC(J)OR10,-OC(J)N(R11)(R12),-Si(R14)3,-N(R10)S(O)tR15和-S(O)tR15; 或R2是任選取代的環(huán)烷基,任選取代的環(huán)烷基烷基,任選取代的雜環(huán)基,任選取代的雜環(huán)烷基,任選取代的芳基,任選取代的雜芳基,任選取代的芳烷基,任選取代的雜芳烷基或任選取代的芳基,當(dāng)取代時,其所有的都被一至五個取代基取代,每個取代基獨立地選自:烷基,鹵代烷基,環(huán)烷基,環(huán)烷基烷基,雜環(huán)基,雜環(huán)烷基,芳基,芳烷基,雜芳基,雜芳烷基,氰基,硝基,鹵素,擬鹵素,-R9-OR10,-R9-SR16,-R9-N(R11)(R12),-R9-C(J)R13,-R9-C(J)OR10,-R9-C(J)N(R11)(R12),-R9-C(J)N(R10)N(R11)(R12),-R9-N(R10)C(J)R13,-R9-N(R10)C(J)OR10,-R9-N(R10)C(J)N(R11)(R12),-R9-OC(J)R13,-R9-OC(J)OR10,-R9-OC(J)N(R11)(R12),-Si(R14)3,-N(R10)S(O)tR15和-R9-S(O)tR15; 或R2是-R9-C(J)R13,-R9-C(J)OR10,-R9-C(J)N(R11)(R12),-R9-C(J)N(R10)N(R11)(R12),-R9-N(R10)C(J)R13,-R9-N(R10)C(J)OR10,-R9-N(R10)C(J)N(R11)(R12),-R9-N(R11)(R12)or-R9-S(O)tR15; R3、R4和R5每個獨立地在如下的(a)、(b)或(c)中選擇: (a)R3、R4和R5每個獨立地是任選取代的烷基,任選取代的烯基或任選取代的炔基,當(dāng)取代時,其所有的都被下列取代:氰基,硝基,鹵素,擬鹵素,-OR10,-SR16,-N(R11)(R12),-C(J)R13,-C(J)OR10,-C(J)N(R11)(R12),-C(J)N(R10)N(R11)(R12),-N(R10)C(J)R13,-N(R10)C(J)OR10,-N(R10)C(J)N(R11)(R12),-OC(J)R13,-OC(J)OR10,-OC(J)N(R11)(R12),-Si(R14)3,-N(R10)S(O)tR15和-S(O)tR15; 或(b)R3、R4和R5每個獨立地是任選取代的環(huán)烷基,任選取代的環(huán)烷基烷基,任選取代的雜環(huán)基,任選取代的雜環(huán)烷基,任選取代的芳基,任選取代的芳烷基,任選取代的雜芳基,或任選取代的雜芳烷基,當(dāng)取代時,其所有的都被一至五個取代基取代,每個取代基獨立地選自:烷基,鹵代烷基,環(huán)烷基,環(huán)烷基烷基,雜環(huán)基,雜環(huán)烷基,芳基,芳烷基,雜芳基,雜芳烷基,氰基,硝基,鹵素,擬鹵素,-R9-OR10,-R9-SR16,-R9-N(R11)(R12),-R9-C(J)R13,-R9-C(J)OR10,-R9-C(J)N(R11)(R12),-R9-N(R10)C(J)R13,-R9-N(R10)C(J)OR10,-R9-N(R10)C(J)N(R11)(R12),-R9-OC(J)R13,-R9-OC(J)OR10,-R9-OC(J)N(R11)(R12),-Si(R14)3,-N(R10)S(O)tR15和-R9-S(O)tR15; 或(c)R3、R4和R5每個獨立地選自下列的基團:氫,鹵素,-N(R7)(R8),-N(R10)C(J)R13,-N(R10)C(J)OR10,-R9-C(J)R13,-N(R10)C(J)N(R11)(R12)和-N(R10)S(O)tR15; 條件是只有當(dāng)鍵a是單鍵時,R5存在; 進一步的條件是: 當(dāng)R3、R4或R5是環(huán)烷基烷基或N(R7)(R8)且鍵a是單鍵時,則R1是被至少兩個選自下面的不同取代基取代的苯基:氰基,-R9-C(J)R13,-R9-C(J)OR10,-R9-C(J)N(R11)(R12),-R9-C(J)N(R10)N(R12)R13,-R9-N(R10)C(J)OR10,-R9-N(R10)C(J)N(R11)(R12),-N(R10)S(O)tR13,-R9-N(R10)C(J)R13,和-R9-N(R11)(R12); 或當(dāng)R3、R4或R5是烷基,烯基,炔基,鹵素,鹵代烷基
|
摘要
|
提供了化合物、組合物和調(diào)節(jié)受體活性的方法。尤其是,提供了調(diào)節(jié)受體活性、和用于治療、預(yù)防或改善一或多種直接或間接地與受體活性有關(guān)的疾病或病癥的癥狀的化合物和組合物。
|
國際公布
|
2006-02-23 WO2006/020680 英
|